Antimicrobial Therapeutics Market

Antimicrobial Therapeutics Market Size

Antimicrobial Therapeutics Market is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 5.8% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 88.6 billion and is projected to reach USD 164.5 billion by the completion of 2034.

Antimicrobial therapies refer to a group of medicines that are used to battle a variety of microbial infections, such as bacteria, viruses, fungi, and parasites. These therapies are designed to prevent microbial development that causes the disease, thus reducing symptoms and promoting recovery. Antibiotics are the keystone of antimicrobial therapy as it targets bacterial infections by either eradicating the bacteria or inhibiting their growth. In addition, antimicrobial therapeutics also include antiviral drugs, along with antifungal medications and antiparasitic treatments. Moreover, research is being done to develop new antimicrobial medicines and improve current therapies to surpass microbial adaptation. Consequently, maintaining the effectiveness of these treatments and preventing antimicrobial resistance requires careful adherence to recommended regimens and the careful use of antibiotics.

Market Highlights

Antimicrobial Therapeutics Market is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2034

Antimicrobial therapeutics market is projected to reach USD 164.5 billion over the forecast period, owing to the rising prevalence of infectious diseases, along with the mounting challenge of antimicrobial resistance, which increases the demand for new treatments. Additionally, innovations in technology and healthcare infrastructure across emerging markets are contributing to the growth of the antimicrobial therapeutic market. The COVID-19 pandemic has further highlighted the importance of antimicrobial medicines and encouraged high investment in R&D activities. Moreover, industry players are frequently using strategic collaborations and acquisitions to strengthen their market positions. Thus, the antimicrobial therapeutics market will experience sustained growth due to the escalating burden of infectious diseases and the need to address antimicrobial resistance.

Source: Fatpos Global

Antimicrobial Therapeutics Market Segmentation

Antibacterial segment will dominate owing to its usage for diverse conditions

Antimicrobial therapeutics market is divided based on Drug Class into Antibacterial, Antivirals, Antifungal, and Antiparasitic. The antibacterial segment is leading the antimicrobial therapeutics market as bacterial infections are extremely diverse and range from mild conditions like strep throat to severe illnesses that require a broad spectrum of antibacterial treatments. Besides, antibiotics are widely used across various medical settings, such as hospitals, clinics, and community health centers. The emergence of antimicrobial resistance has created the urgency for developing efficient antibacterial therapies, which attract investment and research in this segment. Therefore, the antibiotics segment remains important for combating bacterial infections, which solidifies its dominance in the antimicrobial therapeutics market.

Oral segment will lead due to the convenience and affordability of administrating drugs

Antimicrobial Therapeutics Market is segmented based on the Route of Administration into Oral, Tropic, Injectable, and Others. The oral segment is predicted to take the lead in the antimicrobial therapeutics market due to the suitability and accessibility of oral medications for patients. This allows for self-administration and adherence to treatment regimens, which is beneficial in long-term care settings. Additionally, oral formulations present an affordable option as compared to alternate routes, which makes them preferable for patients and healthcare providers. By eliminating the need for special medical personnel or equipment required for injectable treatments, the oral route reduces healthcare costs while empowering patients with high autonomy over their treatment. Therefore, these interconnected factors highlight the vast acceptance of the oral segment in the antimicrobial therapeutics market.

Source: Fatpos Global

Market Dynamics

Growth Drivers

Growing Prevalence of Infectious Diseases to Present Growth Opportunities for the Antimicrobial Therapeutic Industry

Antimicrobial therapeutics market is undergoing enormous growth due to the increasing incidence of infectious diseases. The growth of these pathogens is due to several agents such as urbanization and population growth, which has raised the burden of infectious diseases. In addition, the emergence of new infectious agents and antibiotic-resistant strains has further contributed to this problem as it demands antimicrobial therapies for several illnesses. This tendency is responsible for driving the growth as healthcare systems are trying to meet the growing demand for antimicrobial therapies through the development of new medications and better infection control methods.

Advancements in Technology Will Help in the Adoption of Therapies

Innovations in pharmaceutical research & development are a key driver of the antimicrobial therapeutics market. Discoveries in drug formulation and delivery systems allow for the creation of potent and safer antimicrobial agents. Moreover, improvements in diagnostic technologies provide for the accurate identification of pathogens and help in creating a personalized treatment method. The exploration of new treatment modes, such as immunotherapies and phage therapies, shows promising potential to overcome antimicrobial resistance and therapeutic options. Therefore, technological improvements are responsible for enhancing the efficacy of treatment and the ability to tackle various challenges in the management of infectious diseases.

Restraints

Antimicrobial Resistance May Prevent Growth in the Market

Increasing problem of antimicrobial resistance is a significant limitation of the antimicrobial therapeutics market. The overuse and misuse of antimicrobial agents, along with inadequate infection control measures, have led to the distribution of multidrug-resistant pathogens. Antimicrobial resistance presents a major threat to public health and contributes to high mortality rates. Thus, addressing antimicrobial resistance demands a multilayered approach, such as developing new antimicrobial agents and implementing infection prevention measures to combat drug resistance. Furthermore, despite several efforts, antimicrobial resistance remains a significant challenge that requires sustained attention and investment to reduce its impact on public health.

Recent Developments

• Alembic Pharmaceuticals Limited, a pharmaceutical company, disclosed in August 2020 that it had obtained approval from the U.S. FDA for its anti-fungal Tavaborole Topical Solution, intended for treating onychomycosis of the toenails.
• Mankind Pharma, another pharmaceutical firm, announced the introduction of Posacoazole Gastro-resistant tablets to address black fungus in June 2021.
• Sandoz International GmbH, a prominent provider of off-patent medicines, entered an agreement on January 24, 2023, to acquire global product rights for Mycamine, a leading systemic antifungal agent, from Astellas Pharma Inc., a Japanese pharmaceutical company.
• Pfizer Inc. revealed in 2021 that it had completed the acquisition of Amplyx Pharmaceuticals, Inc., a privately held company focused on developing therapies for severe diseases affecting individuals with weakened immune systems.

Antimicrobial Therapeutics Market

Key Players:

• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Novartis International AG
• Sanofi S.A.
• Roche Holding AG
• AstraZeneca PLC
• Bayer AG
• AbbVie Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Astellas Pharma Inc.
• Gilead Sciences, Inc.
• Boehringer Ingelheim GmbH
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)

Regional Analysis

Antimicrobial Therapeutics Market is segmented based on regional analysis into five key regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America will likely dominate the antimicrobial therapeutics market due to its advanced research infrastructure, strict regulatory standards, and huge healthcare expenditure. In addition, Europe's trend resembles that of North America due to similar disease patterns and increasing healthcare spending. Both regions have high rates of infectious infections, which pushes the demand for effective antimicrobial therapies. Furthermore, collaborative research activities and regulatory compliance help in the development and approval of new medicines. Alongside, improvements in healthcare infrastructure and insurance coverage increase access to antimicrobial therapies. Thus, while North America leads in research and market demand, Europe is closely aligning its growth trajectory as it benefits from expertise and actions to address infectious illnesses and antibiotic resistance.

Source: Fatpos Global

Impact of COVID-19 on Antimicrobial Therapeutics Market

COVID-19 pandemic had a profound impact on the antimicrobial therapeutics market. Initially, there was a rise in the demand for antimicrobial drugs to manage secondary bacterial infections in COVID-19 patients. However, disruptions in healthcare services, such as low hospital visits and elective procedures, resulted in a decline in antimicrobial prescriptions. The pandemic also highlighted the significance of infection prevention and control measures, that led to high awareness and implementation of hygiene practices. Moreover, the pandemic accelerated research efforts toward creating new antiviral therapies. Consequently, while COVID-19 initially impacted the patterns of antimicrobial supply chains, it also highlighted the need for sustainable strategies to combat infectious diseases.

Antimicrobial Therapeutics Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Antimicrobial Therapeutics Market Scope and Segments:

Frequently Asked Questions (FAQ):